Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$100.69 -2.1%	$106.75	$72.21 ▼ $139.13	$5.07B	0.47	678,849 shs	1.15 million shs
SRPT Sarepta Therapeutics	$20.08 -3.3%	$43.10	$18.30 ▼ $173.25	$2.04B	0.61	2.10 million shs	12.63 million shs
TLX Telix Pharmaceuticals	$17.15 +1.1%	$17.07	$13.61 ▼ $30.36	$5.74B	N/A	26,646 shs	161,720 shs
VERA Vera Therapeutics	$20.86 -0.3%	$22.49	$18.53 ▼ $51.61	$1.33B	1.13	962,396 shs	1.34 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-2.14%	-3.28%	-4.79%	-20.59%	+32.45%
SRPT Sarepta Therapeutics	-3.32%	-44.50%	-49.86%	-72.90%	-82.91%
TLX Telix Pharmaceuticals	+1.12%	+6.59%	+2.94%	-3.60%	+1,714,999,900.00%
VERA Vera Therapeutics	-0.29%	-8.27%	+2.31%	-22.97%	-41.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6528 of 5 stars	4.5	2.0	0.0	4.5	1.4	4.2	0.6
SRPT Sarepta Therapeutics	4.5396 of 5 stars	4.2	2.0	0.0	4.2	1.5	1.7	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	2.6091 of 5 stars	4.6	1.0	0.0	0.0	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	71.15% Upside
SRPT Sarepta Therapeutics	2.46	Hold	$67.64	236.85% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.00	28.28% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	211.60% Upside

Current Analyst Ratings Breakdown

Latest VERA, SRPT, TLX, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00
6/17/2025	SRPT Sarepta Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	12.85	N/A	N/A	$1.18 per share	85.33
SRPT Sarepta Therapeutics	$1.90B	1.04	$2.35 per share	8.53	$15.99 per share	1.26
TLX Telix Pharmaceuticals	$516.72M	11.23	$0.12 per share	148.52	$1.12 per share	15.31
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	35.71	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.84	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	35.73	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest VERA, SRPT, TLX, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TLX Telix Pharmaceuticals	0.99	2.78	2.66
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
SRPT Sarepta Therapeutics	86.68%
TLX Telix Pharmaceuticals	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
SRPT Sarepta Therapeutics	7.70%
TLX Telix Pharmaceuticals	N/A
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.25 million	N/A	N/A
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

VERA, SRPT, TLX, and AXSM Headlines

Recent News About These Companies

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by Brokerages

June 20 at 2:22 AM | marketbeat.com

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19 at 1:32 AM | theglobeandmail.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Update

June 18 at 11:04 AM | marketbeat.com

Brokers Offer Predictions for VERA FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Wedbush Equities Analysts Raise Earnings Estimates for VERA

June 13, 2025 | americanbankingnews.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Comments on VERA FY2026 Earnings

June 11, 2025 | marketbeat.com

Q2 EPS Estimates for Vera Therapeutics Increased by Wedbush

June 11, 2025 | marketbeat.com

Vera Therapeutics Inc.

June 10, 2025 | barrons.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025 | globenewswire.com

Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What Happened

June 9, 2025 | marketbeat.com

Otsuka, Vera stake their claims to IgAN treatment

June 9, 2025 | pharmaphorum.com

Otsuka's kidney disease therapy trial results heat up battle with rival Vera

June 6, 2025 | msn.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?

June 6, 2025 | marketbeat.com

Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

June 6, 2025 | marketbeat.com

Wedbush Increases Earnings Estimates for Vera Therapeutics

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

June 5, 2025 | marketbeat.com

Scotiabank Increases the Price Target for Vera Therapeutics by $10

June 4, 2025 | msn.com

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)

June 4, 2025 | seekingalpha.com

FY2025 EPS Estimate for Vera Therapeutics Lowered by Analyst

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA, SRPT, TLX, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$100.69 -2.20 (-2.14%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$105.40 +4.71 (+4.68%)

As of 06/20/2025 05:12 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Sarepta Therapeutics NASDAQ:SRPT

$20.08 -0.69 (-3.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$20.10 +0.02 (+0.10%)

As of 06/20/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$17.15 +0.19 (+1.12%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$17.00 -0.15 (-0.87%)

As of 06/20/2025 05:08 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Vera Therapeutics NASDAQ:VERA

$20.86 -0.06 (-0.29%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$21.04 +0.19 (+0.89%)

As of 06/20/2025 07:10 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time